Medifast, Inc.
NYSE:MEDPersonal Products & Services
-$0.01 today
- Market cap
- $136.43M
- Beta
- 0.66
- P/E (TTM)
- -6.2
- EPS (TTM)
- -$1.82
Volume 0.09M
Average 0.21M
MED Cost of Revenue
Direct costs of producing the goods and services sold, such as materials, manufacturing, and service delivery.
Medifast, Inc.NYSE: MED
Cost of Revenue · Q1 FY2026 · quarter ended Mar 2026
Cost of revenue declines year over year
Q1 FY2026 cost of revenue of $24.29M fell 22.9% year over year, ahead of the -27.1% change in trailing-twelve-month cost of revenue. Sequentially, it rose 5.8% from the prior quarter. Over 3 fiscal years it compounded at -37.7% a year.
Context
- Cost of revenue amounted to 28.7% of revenue in FY2025, up 2.5 pp from a year earlier.
- Cost of revenue increased in 0 of the last 3 fiscal years.
- FY2025 was the lowest annual figure in the 4 fiscal years shown.
What to watch
Whether quarterly growth of -22.9% holds above the trailing-twelve-month pace of -27.1%.
Sources:Income StatementText generated from reported figures; not investment advice.
Cost of Revenue history
USD · from the income statement
- Latest · FY2025
- 110.6M USD
- Year-over-year change
- -29.9%
- 4-year CAGR
- -27.4%
| Period | Period end | Cost of Revenue | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | 110.6M | -29.9% |
| FY2024 | 2024-12-31 | 157.84M | -46.7% |
| FY2023 | 2023-12-31 | 296.2M | -35.3% |
| FY2022 | 2022-12-31 | 458.16M | +15.0% |
| FY2021 | 2021-12-31 | 398.49M | — |
Cost of Revenue vs competitors
How MED compares with its peers on the latest reported figures
- Peers report in different currencies, so cost of revenue is compared through growth and share of revenue rather than absolute size.
- Its year-over-year change of -27.1% is the 9th highest of 10, against a peer median of -0.5%.
- Cost of revenue amounts to 29.9% of revenue for MED, versus a peer median of 66.0%.
| Company | Period | LTM | YoY | 3-year CAGR | % of revenue |
|---|---|---|---|---|---|
| LTM May 2026 | $646.55M USD | -6.4% | -7.7% | 66.0% | |
| LTM Dec 2025 | $620.27M USD | +14.5% | +11.6% | 81.0% | |
| FY2025 | HK$316.89M HKD | -4.7% | +25.3% | 69.0% | |
| LTM Mar 2026 | $249.98M USD | -0.4% | -0.1% | 41.4% | |
| LTM Jan 2026 | $204.51M USD | +27.4% | +5.9% | 71.1% | |
| LTM Mar 2026 | $170.14M USD | +2.0% | -6.6% | 67.4% | |
| LTM Feb 2026 | $146.44M USD | -0.5% | -14.8% | 43.9% | |
| LTM Mar 2026 | $103.41M USD | -27.1% | -37.7% | 29.9% | |
| LTM Mar 2026 | $23.67M USD | -5.3% | -6.6% | 26.5% | |
AIIORobo.ai Inc. | FY2025 | $356K USD | -96.2% | — | 37.5% |
| Peer median (excluding MED) | — | -0.5% | -3.3% | 66.0% | |
Competitors are the stored peer set for MED. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Income Statement
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Revenue | 1.53B | 1.6B | 1.07B | 602.46M | 385.79M |
| Cost of Revenue | 398.49M | 458.16M | 296.2M | 157.84M | 110.6M |
| Gross Profit | 1.13B | 1.14B | 775.85M | 444.62M | 275.19M |
| Gross Margin | 73.9% | 71.3% | 72.4% | 73.8% | 71.3% |
| Research & Development | 0 | 0 | 0 | 0 | 0 |
| Selling, General & Admin | 911.36M | 955.61M | 649.45M | 441.75M | 289.4M |
| Operating Expenses | 911.36M | 955.61M | 649.45M | 441.75M | 289.4M |
| Depreciation & Amortization | 6.81M | 10.98M | 13.11M | 12.71M | 10.5M |
| EBITDA | 222.94M | 195.74M | 141.9M | 16.49M | 4.86M |
| EBITDA Margin | 14.6% | 12.2% | 13.2% | 2.7% | 1.3% |
| Operating Income | 216.24M | 184.81M | 126.4M | 2.88M | (14.21M) |
| Operating Margin | 14.2% | 11.6% | 11.8% | 0.5% | -3.7% |
| Interest Income | 0 | 0 | 2.49M | 4.8M | 5.52M |
| Interest Expense | 231K | 701K | 0 | 0 | 0 |
| Other Income / Expenses | (112K) | (747K) | 2.4M | 909K | 8.57M |
| Income Before Tax | 216.13M | 184.06M | 128.8M | 3.79M | (5.64M) |
| Pre-Tax Margin | 14.2% | 11.5% | 12.0% | 0.6% | -1.5% |
| Income Tax Expense | 52.1M | 40.49M | 29.38M | 1.7M | 13.03M |
| Net Income | 164.03M | 143.57M | 99.42M | 2.09M | (18.67M) |
| Net Margin | 10.7% | 9.0% | 9.3% | 0.3% | -4.8% |
| EPS (Basic) | 14.01 | 12.82 | 9.10 | 0.19 | (1.70) |
| EPS (Diluted) | 13.89 | 12.73 | 9.10 | 0.19 | (1.70) |
| Weighted Avg Shares | 11.71M | 11.2M | 10.88M | 10.93M | 10.98M |
| Weighted Avg Shares (Diluted) | 11.81M | 11.28M | 10.92M | 10.96M | 10.98M |
Medifast, Inc.
NYSE:MED
Intrinsic Alpha fair value
Locked
Current Price
$12.20
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.